Successful Treatment of Antihypertensive Overdose Using Intravenous Angiotensin II.

Background: Despite multiple treatment options, antihypertensive overdose remains a cause of significant morbidity and mortality. Intravenous angiotensin II (AG II) is approved for use in vasodilatory shock. We describe 2 cases of refractory shock from antihypertensive overdose that were successfully treated using AG II.

Review of multi-person exposure calls to a regional poison control center.

Objective: Poisoning events, including exposures to hazardous materials, can involve multiple victims. Regional poison centers often are contacted in such events involving multiple victims.

Methods: We searched our poison center database over a nine-year time period for all calls involving a poisoning event in which more than two people were exposed to the same substance.

Medical toxicology and public health--update on research and activities at the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry inhalational methanol toxicity.

Methanol toxicity is still a relatively common poisoning worldwide. Exposure typically occurs through ingestion, but there is potential for occupational inhalational exposures as well. People with potential exposure to methanol in any form need to wear the appropriate personal protective equipment, and they need to be familiar with proper detection methods.

Update on research and activities at the Centers for Disease Control and Prevention, and the agency for toxic substances and disease registry.

The true cause of this particular outbreak has yet to be determined, however, outbreaks of PA-associated toxicity are a global public health problem. These outbreaks have caused significant morbidity and mortality in both animals and humans. It is important to consider PA toxicity in the differential for liver disease of unknown origin, and it is probably more important to do so in developing countries.

Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

750 mg per day of acetazolamide in the prevention of acute mountain sickness (AMS), as recommended in the meta-analysis published in 2000 in the British Medical Journal, may be excessive and is controversial. To determine if the efficacy of low-dose acetazolamide 125 mg bd (250 mg), as currently used in the Himalayas, is significantly different from 375 mg bd (750 mg) of acetazolamide in the prevention of AMS, we designed a prospective, double-blind, randomized, placebo-controlled trial. The participants were sampled from a diverse population of (non-Nepali) trekkers at Namche Bazaar (3440 m) in Nepal on the Everest trekking route as they ascended to study midpoints (4280 m/4358 m) and the endpoint, Lobuje (4928 m), where data were collected.